IQVIA Holdings Inc. (NYSE:IQV) Short Interest Down 15.8% in August

IQVIA Holdings Inc. (NYSE:IQV) was the target of a large decline in short interest in August. As of August 31st, there was short interest totalling 2,770,000 shares, a decline of 15.8% from the August 15th total of 3,290,000 shares. Based on an average trading volume of 1,190,000 shares, the short-interest ratio is currently 2.3 days. Approximately 1.5% of the shares of the stock are short sold.

IQVIA Trading Down 0.0 %

Shares of IQVIA stock traded down $0.03 during trading on Monday, reaching $238.67. 376,178 shares of the stock were exchanged, compared to its average volume of 1,069,572. The stock’s fifty day moving average is $237.98 and its 200 day moving average is $234.26. IQVIA has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm has a market cap of $43.51 billion, a price-to-earnings ratio of 32.61, a price-to-earnings-growth ratio of 2.24 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same quarter last year, the firm posted $2.22 earnings per share. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, equities research analysts expect that IQVIA will post 10.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of several research analyst reports. Morgan Stanley upped their price target on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Evercore ISI boosted their price target on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Finally, Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $266.67.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is owned by company insiders.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently bought and sold shares of the company. SS&H Financial Advisors Inc. purchased a new stake in shares of IQVIA during the second quarter valued at $235,000. Sanctuary Advisors LLC bought a new position in IQVIA during the second quarter valued at approximately $803,000. Brown Financial Advisors purchased a new stake in IQVIA in the second quarter worth approximately $642,000. Dana Investment Advisors Inc. raised its stake in IQVIA by 7.4% during the 2nd quarter. Dana Investment Advisors Inc. now owns 87,145 shares of the medical research company’s stock valued at $18,426,000 after buying an additional 6,019 shares during the last quarter. Finally, Cetera Investment Advisers lifted its holdings in shares of IQVIA by 3.3% during the 2nd quarter. Cetera Investment Advisers now owns 71,602 shares of the medical research company’s stock valued at $15,140,000 after buying an additional 2,272 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.